StockData
AbbVie Inc. logo

AbbVie Inc.

ABBVNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 3, 2026Score 10/3094% above fair value
$288.84−6.05 (-2.05%)

Close on Nov 2, 2026Market cap $510.41BP/E 81.6Yield 2.30%

AbbVie United States — Reported revenue growth YoY by Quarter

United States — Reported revenue growth YoY (%) (%)

QuarterlyAnnual

AbbVie United States — Reported revenue growth YoY: 9.3% in Q2 2026, up 3.4 pts from a year earlier.

Latest, Q2 2026
9.3%
Period ended Jun 30, 2026
Change on a year earlier
+3.4 pts
5.9% in Q2 2025
History
23 quarters
Since Q1 2018
Sources
23
Documents cited below

Where the Q2 2026 figure comes from

“|| NET REVENUES | $12,861 | $4,129 | $16,990 | 9.3% | 12.8% | 10.2% | 10.2% | 9.5%”

Source: Form 8-K (abbv-20260630xexhibit991.htm, filed 2026-07-31) ↗

Reported in Form 8-K Key Product Revenues.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedUnited States — Reported revenue growth YoY (%) (%)Year on yearSource
Q2 2026Jun 30, 20269.3%+3.4 ptsForm 8-K (abbv-20260630xexhibit991.htm, filed 2026-07-31) ↗
Q1 2026Mar 31, 20269.9%-0.5 ptsForm 8-K (abbv-20260331xexhibit991.htm, filed 2026-04-29) ↗
Q4 2025Dec 31, 20259.0%+3.4 ptsForm 8-K (abbv-20251231xexhibit991.htm, filed 2026-02-04) ↗
Q3 2025Sep 30, 20258.2%+5.5 ptsForm 8-K (abbv-20250930xexhibit991.htm, filed 2025-10-31) ↗
Q2 2025Jun 30, 20255.9%+2.3 ptsForm 8-K (abbv-20250630xexhibit991.htm, filed 2025-07-31) ↗
Q1 2025Mar 31, 202510.4%+12.1 ptsForm 8-K (abbv-20250331xexhibit991.htm, filed 2025-04-25) ↗
Q4 2024Dec 31, 20245.6%+14.5 ptsForm 8-K (abbv-20241231xexhibit991.htm, filed 2025-01-31) ↗
Q3 2024Sep 30, 20242.7%+10.4 ptsForm 8-K (abbv-20240930xexhibit991.htm, filed 2024-10-30) ↗
Q2 2024Jun 30, 20243.6%+9.6 ptsForm 8-K (abbv-20240630xexhibit991.htm, filed 2024-07-25) ↗
Q1 2024Mar 31, 2024-1.7%+9.4 ptsForm 8-K (abbv-20240331xexhibit991.htm, filed 2024-04-26) ↗
Q4 2023Dec 31, 2023-8.9%-13.3 ptsForm 8-K (abbv-20231231xexhibit991.htm, filed 2024-02-02) ↗
Q3 2023Sep 30, 2023-7.7%-12.0 ptsForm 8-K (abbv-20230930xexhibit991.htm, filed 2023-10-27) ↗
Q2 2023Jun 30, 2023-6.0%-11.6 ptsForm 8-K (abbv-20230630xexhibit991.htm, filed 2023-07-27) ↗
Q1 2023Mar 31, 2023-11.1%-17.2 ptsForm 8-K (abbv-20230331xexhibit991.htm, filed 2023-04-27) ↗
Q4 2022Dec 31, 20224.4%-5.1 ptsForm 8-K (abbv-20221231xexhibit991.htm, filed 2023-02-09) ↗
Q3 2022Sep 30, 20224.3%–Form 8-K (abbv-20220930xexhibit991.htm, filed 2022-10-28) ↗

Cite this data

StockData. (2026). AbbVie United States — Reported revenue growth YoY (%), quarterly Q1 2018–Q2 2026 [Data set]. Compiled from AbbVie SEC filings and investor materials. https://stockdatahq.com/stocks/abbv/kpis/rev-total-us-rep-yoy

See every metric in the AbbVie KPI table. Data updated Oct 26, 2026.